1. Home
  2. KPTI vs AVTX Comparison

KPTI vs AVTX Comparison

Compare KPTI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • AVTX
  • Stock Information
  • Founded
  • KPTI 2008
  • AVTX 2011
  • Country
  • KPTI United States
  • AVTX United States
  • Employees
  • KPTI N/A
  • AVTX N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KPTI Health Care
  • AVTX Health Care
  • Exchange
  • KPTI Nasdaq
  • AVTX Nasdaq
  • Market Cap
  • KPTI 81.1M
  • AVTX 88.4M
  • IPO Year
  • KPTI 2013
  • AVTX 2015
  • Fundamental
  • Price
  • KPTI $0.62
  • AVTX $7.35
  • Analyst Decision
  • KPTI Strong Buy
  • AVTX Strong Buy
  • Analyst Count
  • KPTI 4
  • AVTX 4
  • Target Price
  • KPTI $5.00
  • AVTX $33.00
  • AVG Volume (30 Days)
  • KPTI 768.4K
  • AVTX 54.4K
  • Earning Date
  • KPTI 02-19-2025
  • AVTX 03-28-2025
  • Dividend Yield
  • KPTI N/A
  • AVTX N/A
  • EPS Growth
  • KPTI N/A
  • AVTX N/A
  • EPS
  • KPTI N/A
  • AVTX N/A
  • Revenue
  • KPTI $148,442,000.00
  • AVTX $820,000.00
  • Revenue This Year
  • KPTI $4.47
  • AVTX N/A
  • Revenue Next Year
  • KPTI $7.35
  • AVTX N/A
  • P/E Ratio
  • KPTI N/A
  • AVTX N/A
  • Revenue Growth
  • KPTI 1.77
  • AVTX N/A
  • 52 Week Low
  • KPTI $0.58
  • AVTX $4.18
  • 52 Week High
  • KPTI $1.70
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • AVTX 42.79
  • Support Level
  • KPTI $0.58
  • AVTX $7.42
  • Resistance Level
  • KPTI $0.67
  • AVTX $8.50
  • Average True Range (ATR)
  • KPTI 0.05
  • AVTX 0.64
  • MACD
  • KPTI -0.00
  • AVTX 0.02
  • Stochastic Oscillator
  • KPTI 31.02
  • AVTX 17.16

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: